ALDAGEN

ALDAGEN is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We have four product candidates in clinical trials. Our most advanced product candidate is ALD-101. We are currently conducting a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improving umbilical cord blood, or cord blood, transplants used to treat inherited metabolic diseases in pediatric patients. We are also conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates—ALD-151 to improve cord blood transplants used for the treatment of leukemia; ALD-301 to treat critical limb ischemia; and ALD-201 to treat ischemic heart failure.

This site is currently down for revisions.

5.12.08 - Download PDF
Aldagen Files Registration Statement for Initial Public Offering

4.23.08 - Download PDF
Aldagen Secures $18.4 Million in Financing

4.15.08 - Download PDF
Initiation of ALD-101 Phase III Trial for Improving Cord Blood Transplants ...